Cargando…

The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases

BACKGROUND: Metastatic breast cancer (MBC) prognosis is variable, depending on several clinical and biological factors. A better prediction of a patient’s outcome could allow for a more accurate choice of treatments. The role of serum biomarkers in predicting outcome remains unclear in this setting....

Descripción completa

Detalles Bibliográficos
Autores principales:	Darlix, Amélie, Hirtz, Christophe, Thezenas, Simon, Maceski, Aleksandra, Gabelle, Audrey, Lopez-Crapez, Evelyne, De Forges, Hélène, Firmin, Nelly, Guiu, Séverine, Jacot, William, Lehmann, Sylvain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354387/ https://www.ncbi.nlm.nih.gov/pubmed/30700265 http://dx.doi.org/10.1186/s12885-019-5287-z

Ejemplares similares

Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients
por: Darlix, Amélie, et al.
Publicado: (2016)

Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry
por: Bros, Pauline, et al.
Publicado: (2015)

Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer
por: Viala, Marie, et al.
Publicado: (2021)

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification
por: Barthélemy, Nicolas R., et al.
Publicado: (2020)

From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid
por: Hirtz, Christophe, et al.
Publicado: (2016)

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
por: Delaby, Constance, et al.
Publicado: (2022)

Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLM(R) Scale
por: Lehmann, Sylvain, et al.
Publicado: (2018)

Clinicopathological Correlates of γδ T Cell Infiltration in Triple-Negative Breast Cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2021)

Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles
por: Jacot, William, et al.
Publicado: (2011)

Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals
por: Lehmann, Sylvain, et al.
Publicado: (2020)

Inflammatory Blood Markers as Prognostic and Predictive Factors in Early Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
por: Corbeau, Ileana, et al.
Publicado: (2020)

Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2022)

Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers
por: Guiu, Séverine, et al.
Publicado: (2018)

Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
por: Alexandre, Marie, et al.
Publicado: (2019)

Identification of multiple proteoforms biomarkers on clinical samples by routine Top-Down approaches
por: Vialaret, Jerome, et al.
Publicado: (2018)

BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer
por: Jacot, William, et al.
Publicado: (2013)

Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study
por: Jacot, William, et al.
Publicado: (2010)

Comparative performances of prognostic indexes for breast cancer patients presenting with brain metastases
por: Braccini, Antoine-Laurent, et al.
Publicado: (2013)

High Levels of Cartilage Oligomeric Matrix Protein in the Serum of Breast Cancer Patients Can Serve as an Independent Prognostic Marker
por: Papadakos, Konstantinos S., et al.
Publicado: (2019)

BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer
por: Jacot, William, et al.
Publicado: (2020)

Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review
por: Corbeau, Iléana, et al.
Publicado: (2020)

Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function
por: Lehmann, Sylvain, et al.
Publicado: (2023)

Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects
por: Leenhardt, Fanny, et al.
Publicado: (2022)

New Perspectives of Multiplex Mass Spectrometry Blood Protein Quantification on Microsamples in Biological Monitoring of Elderly Patients
por: Vialaret, Jérôme, et al.
Publicado: (2023)

Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort
por: Hirtz, Christophe, et al.
Publicado: (2023)

Hypocretin and brain β-amyloid peptide interactions in cognitive disorders and narcolepsy
por: Dauvilliers, Yves A., et al.
Publicado: (2014)

BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib
por: Velazquez, Carolina, et al.
Publicado: (2023)

Prognostic impact of extracranial disease control in HER2+ breast cancer-related brain metastases
por: Bottosso, Michele, et al.
Publicado: (2023)

Editorial: Proteomics as a Tool for Biomarker and Drug Target Discovery: Improving the Diagnosis and Treatment of Neurodegenerative Diseases
por: Belbin, Olivia, et al.
Publicado: (2020)

Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer’s disease and other proteinopathies
por: Mohaupt, Pablo, et al.
Publicado: (2023)

Neurofilament-Light, a Promising Biomarker: Analytical, Metrological and Clinical Challenges
por: Coppens, Salomé, et al.
Publicado: (2023)

Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real‐world data from a multicentric European cohort
por: Ratosa, Ivica, et al.
Publicado: (2022)

A comprehensive profiling of the immune microenvironment of breast cancer brain metastases
por: Griguolo, Gaia, et al.
Publicado: (2022)

Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer
por: Bobrie, Angélique, et al.
Publicado: (2022)

Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ(1–42) and Tau Proteins in Elderly Patients With Mild Cognitive Impairment
por: Duron, Emmanuelle, et al.
Publicado: (2018)

Corrigendum: Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aß(1−42), and Tau Proteins in Elderly Patients With Mild Cognitive Impairment
por: Duron, Emmanuelle, et al.
Publicado: (2019)

The alternative proteome in neurobiology
por: Mohaupt, Pablo, et al.
Publicado: (2022)

Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity
por: Ayrignac, Xavier, et al.
Publicado: (2020)

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers
por: Jacot, William, et al.
Publicado: (2021)

Serum neurofilament light and tau as prognostic markers for all-cause mortality in the elderly general population—an analysis from the MEMO study
por: Rübsamen, Nicole, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fp6kie5u7n34us34ivmi39d2n9